Moderna’s Shift to Cancer Company Lifts Stock Up 177%

The New York Times – Business:

The company’s fortunes cratered as demand for Covid-19 vaccines plummeted. But it was busy working on something else.

Rebecca Robbins
Author: Rebecca Robbins

This post first appeared in The New York Times – Business. Read the original article.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *